Amylin-Based Therapies in Obesity Management

Davies MJ, Bajaj HS, Broholm C, et al; REDEFINE 2 Study Group. N Engl J Med. 2025;393(7):648-659.

Coadministered cagrilintide and semaglutide in adults with overweight or obesity

Garvey WT, Blüher M, Osorto Contreras CK, et al; REDEFINE 1 Study Group. N Engl J Med. 2025;393(7):635-647. 

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

Gasiorek A, Heydorn A, Gabery S, et al. Lancet. 2025;406(10499):135-148.

Amylin: pharmacology, physiology, and clinical potential

Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Pharmacol Rev. 2015;67(3):564-600.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Lau DCW, Erichsen L, Francisco AM, et al. Lancet. 2021;398(10317):2160-2172.

Amylin: from mode of action to future clinical potential in diabetes and obesity

Walker CS, Aitken JF, Amarsingh GV, et al. Nat Rev Endocrinol. 2025;21(8):482-494.